205 related articles for article (PubMed ID: 34383101)
1. Comparison of the effects between MPL and JAK2V617F on thrombosis and peripheral blood cell counts in patients with essential thrombocythemia: a meta-analysis.
Yang E; Wang M; Wang Z; Li Y; Wang X; Ming J; Xiao H; Quan R; Liu W; Hu X
Ann Hematol; 2021 Nov; 100(11):2699-2706. PubMed ID: 34383101
[TBL] [Abstract][Full Text] [Related]
2. Clinical and Hematological Relevance of JAK2V617F, CALR, and MPL Mutations in Vietnamese Patients with Essential Thrombocythemia.
Vu HA; Thao TT; Dong CV; Vuong NL; Chuong HQ; Van PNT; Nghia H; Binh NT; Dung PC; Xinh PT
Asian Pac J Cancer Prev; 2019 Sep; 20(9):2775-2780. PubMed ID: 31554376
[TBL] [Abstract][Full Text] [Related]
3. JAK2 V617F, MPL, and CALR mutations in essential thrombocythaemia and major thrombotic complications: a single-institute retrospective analysis.
Pósfai É; Marton I; Király PA; Kotosz B; Kiss-László Z; Széll M; Borbényi Z
Pathol Oncol Res; 2015 Jul; 21(3):751-8. PubMed ID: 25573593
[TBL] [Abstract][Full Text] [Related]
4.
Furuya C; Hashimoto Y; Morishita S; Inano T; Ochiai T; Shirane S; Edahiro Y; Araki M; Ando M; Komatsu N
Hematology; 2023 Dec; 28(1):2229131. PubMed ID: 37378567
[TBL] [Abstract][Full Text] [Related]
5. The impact of JAK2V617F mutation on different types of thrombosis risk in patients with essential thrombocythemia: a meta-analysis.
Qin Y; Wang X; Zhao C; Wang C; Yang Y
Int J Hematol; 2015 Aug; 102(2):170-80. PubMed ID: 25997869
[TBL] [Abstract][Full Text] [Related]
6. Essential thrombocythaemia with mutation in
Alvarez-Larran A; Martínez D; Arenillas L; Rubio A; Arellano-Rodrigo E; Hernández Boluda JC; Papaleo N; Caballero G; Martínez C; Ferrer-Marín F; Mata MI; Pérez-Encinas M; Durán MA; Alonso JM; Carreño-Tarragona G; Alonso JM; Noya S; Magro E; Pérez R; López-Guerra M; Pastor-Galán I; Cervantes F; Besses C; Colomo L; Rozman M
J Clin Pathol; 2018 Nov; 71(11):975-980. PubMed ID: 29934356
[TBL] [Abstract][Full Text] [Related]
7. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia.
Vannucchi AM; Antonioli E; Guglielmelli P; Pancrazzi A; Guerini V; Barosi G; Ruggeri M; Specchia G; Lo-Coco F; Delaini F; Villani L; Finotto S; Ammatuna E; Alterini R; Carrai V; Capaccioli G; Di Lollo S; Liso V; Rambaldi A; Bosi A; Barbui T
Blood; 2008 Aug; 112(3):844-7. PubMed ID: 18519816
[TBL] [Abstract][Full Text] [Related]
8. Thrombotic risk correlates with mutational status in true essential thrombocythemia.
Bertozzi I; Peroni E; Coltro G; Bogoni G; Cosi E; Santarossa C; Fabris F; Randi ML
Eur J Clin Invest; 2016 Aug; 46(8):683-9. PubMed ID: 27271054
[TBL] [Abstract][Full Text] [Related]
9. Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L/K mutations.
Okabe M; Yamaguchi H; Usuki K; Kobayashi Y; Kawata E; Kuroda J; Kimura S; Tajika K; Gomi S; Arima N; Mori S; Ito S; Koizumi M; Ito Y; Wakita S; Arai K; Kitano T; Kosaka F; Dan K; Inokuchi K
Leuk Res; 2016 Jan; 40():68-76. PubMed ID: 26614694
[TBL] [Abstract][Full Text] [Related]
10. Is the absence of JAK2 mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients.
Patriarca A; Pompetti F; Malizia R; Iuliani O; Di Marzio I; Spadano A; Dragani A
Blood Transfus; 2010 Jan; 8(1):21-7. PubMed ID: 20104275
[TBL] [Abstract][Full Text] [Related]
11. Comparison between thrombotic risk scores in essential thrombocythemia and survival implications.
Santoro M; Accurso V; Mancuso S; Carlisi M; Raso S; Tarantino G; Di Piazza F; Perez A; Russo A; Siragusa S
Hematol Oncol; 2019 Oct; 37(4):434-437. PubMed ID: 31465530
[TBL] [Abstract][Full Text] [Related]
12. JAK2V617F mutation and circulating extracellular vesicles in essential thrombocythemia.
Aswad MH; Kissova J; Ovesna P; Říhová L; Penka M
Clin Hemorheol Microcirc; 2023; 84(4):359-368. PubMed ID: 37334581
[TBL] [Abstract][Full Text] [Related]
13. The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia.
Hsiao HH; Yang MY; Liu YC; Lee CP; Yang WC; Liu TC; Chang CS; Lin SF
Exp Hematol; 2007 Nov; 35(11):1704-7. PubMed ID: 17920754
[TBL] [Abstract][Full Text] [Related]
14. Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history.
Gangat N; Wassie EA; Lasho TL; Finke C; Ketterling RP; Hanson CA; Pardanani A; Wolanskyj AP; Maffioli M; Casalone R; Passamonti F; Tefferi A
Eur J Haematol; 2015 Jan; 94(1):31-6. PubMed ID: 24889737
[TBL] [Abstract][Full Text] [Related]
15. JAK2V617F allele burden is associated with thrombotic mechanisms activation in polycythemia vera and essential thrombocythemia patients.
Coucelo M; Caetano G; Sevivas T; Almeida Santos S; Fidalgo T; Bento C; Fortuna M; Duarte M; Menezes C; Ribeiro ML
Int J Hematol; 2014 Jan; 99(1):32-40. PubMed ID: 24277659
[TBL] [Abstract][Full Text] [Related]
16. Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia.
Chen CC; Gau JP; Chou HJ; You JY; Huang CE; Chen YY; Lung J; Chou YS; Leu YW; Lu CH; Lee KD; Tsai YH
Ann Hematol; 2014 Dec; 93(12):2029-36. PubMed ID: 25015052
[TBL] [Abstract][Full Text] [Related]
17. Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients.
Haider M; Gangat N; Lasho T; Abou Hussein AK; Elala YC; Hanson C; Tefferi A
Am J Hematol; 2016 Jun; 91(4):390-4. PubMed ID: 26799697
[TBL] [Abstract][Full Text] [Related]
18. Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018.
Mejía-Ochoa M; Acevedo Toro PA; Cardona-Arias JA
BMC Cancer; 2019 Jun; 19(1):590. PubMed ID: 31208359
[TBL] [Abstract][Full Text] [Related]
19. Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET).
Zhao S; Zhang X; Xu Y; Feng Y; Sheng W; Cen J; Wu D; Han Y
Int J Med Sci; 2016; 13(1):85-91. PubMed ID: 26917989
[TBL] [Abstract][Full Text] [Related]
20. Molecular biomarkers of thrombosis in myeloproliferative neoplasms.
Barbui T; Falanga A
Thromb Res; 2016 Apr; 140 Suppl 1():S71-5. PubMed ID: 27067982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]